Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.
← catalyst calendarNCT07154238 · readout in 42 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
2,546estimated
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-26 | actual | When the study began enrolling |
| Primary completion | 2026-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Intervention
- Other: No treatment given
Primary outcomes
what the primary-completion date above is the date OFDescription of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management
measured At the time of survey response (Day 1)
Description of the experience of individuals initiated on injectable semaglutide for weight management through personal perception of physical and mental health and self-reported QoL
measured At the time of survey response (Day 1)
Individual-reported change in BMI since initiation
measured At the time of survey response (Day 1)
Individual-reported achievement of weight loss goal
measured At the time of survey response (Day 1)
Individual-reported change in weight since initiation
measured At the time of survey response (Day 1)
Individual-reported changes in daily life since initiation on injectable semaglutide
measured At the time of survey response (Day 1)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed